More on NRSN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.0 Score)

Upcoming Events

- Earnings (9/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Neurosense Therapeutics (NQ:NRSN)
Delayed: 0.68 -0.02 (2.86%)
Prev. Close $0.70  
Open$0.71 
52 Wk High$ 
52 Wk Low$ 
Day High$0.73 
Day Low$0.68 
P/E N/A  
EPS$ 
Volume55,333 

Friends, Peers and Foes (?): H1Z NRSNW (more...)

Jul 6, 2026 08:45 AM NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
Jun 29, 2026 09:30 AM NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial
Jun 29, 2026 09:30 AM Form 6-K NeuroSense Therapeutics For: Jun 29
Jun 29, 2026 09:30 AM NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
Jun 25, 2026 09:25 AM Form 6-K NeuroSense Therapeutics For: Jun 25
Jun 25, 2026 09:20 AM NeuroSense reports biomarker findings from small Alzheimer's PrimeC trial
Jun 25, 2026 09:20 AM NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
Jun 22, 2026 09:00 AM EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
Jun 17, 2026 04:30 PM Form 4 NeuroSense Therapeutics For: Jun 16 Filed by: Eisenberg Or
Jun 17, 2026 04:30 PM Form 4 NeuroSense Therapeutics For: Jun 16 Filed by: Ben-Noon Alon
View All Articles

Entities mentioned with NRSN

View All Entities